Synthetic 'poop' can cure C. difficile infection, study finds

A synthetic "poop" developed at the University of Guelph can cure nasty gastrointestinal infections caused by Clostridium difficile, a toxin-producing bacterium.

A study on the artificial stool was published today in the inaugural issue of Microbiome, a new peer-reviewed science journal.

The stool – a "super-probiotic" called RePOOPulate – was created by Guelph microbiologist Emma Allen-Vercoe to replace human fecal matter used in stool transplants, a known treatment for C. difficile.

She made the super-probiotic from purified intestinal grown in "Robo-gut" equipment in a Guelph laboratory that mimics the environment of the .

Besides offering an against the deadly superbug, the artificial poop is safer, more stable and adaptable, and less "icky" than treatments for C. difficile infection such as fecal bacteriotherapy, the study said.

"It's an exciting finding," said Allen-Vercoe, a professor in Guelph's Department of .

She worked on the project with lead researchers Dr. Elaine Petrof, an infectious disease specialist at Kingston General Hospital and a professor at Queen's University, and Gregory Gloor, a biochemistry professor at the University of Western Ontario. Guelph pathobiology professor Scott Weese and researcher Michelle Daigneault were also involved.

C. difficile can overpopulate the colon when antibiotics kill healthy . C. difficile infection causes many , including severe diarrhea, and often leads to outbreaks in hospitals and long-term care facilities.

Few treatments exist for people with recurring C. difficile infections. Stool transplants are among the more effective therapies, but human fecal matter may contain unknown pathogens, Allen-Vercoe said. "That puts people at risk for future disease."

Stool transplants are also limited by lack of acceptance among patients and health-care facilities and lack of standardized treatment regimens.

Using synthetic poop for transplants eliminates the risk of transmitting an infectious disease through fecal bacteria because "the exact composition of the bacteria administered is known and can be controlled," Allen-Vercoe said.

The method may be modified to suit individual patient needs, is easily reproduced, and is more appealing to many patients and physicians, she said.

The researchers tested RePOOPulate on two patients with chronic C. difficile infections who had previously failed to respond to several rounds of antibiotics. After treatment with the synthetic poop, both were symptom-free within three days and tested negative for C. difficile six months later.

As well, later microbial profiles of both patients showed that some features of the synthetic stool stabilized in their colons. "In other words, the introduced microbes were able to persist," Allen-Vercoe said. "This is important because most commercially available probiotics only colonize transiently."

Allen-Vercoe hopes doctors will one day use the RePOOPulate concept to treat other GI conditions, such as inflammatory bowel disease, obesity and even autism by replacing abnormal gut microbial ecosystems.

Related Stories

Synthetic stool a prospective treatment for C. difficile

Apr 30, 2012

A synthetic mixture of intestinal bacteria could one day replace stool transplants as a treatment for Clostridium difficile (C. difficile). C. difficile is a toxin-producing bacteria that can overpopulate the colon when antib ...

Dogs can accurately sniff out 'superbug' infections

Dec 13, 2012

Dogs can sniff out Clostridium difficile (the infective agent that is responsible for many of the dreaded "hospital acquired infections") in stool samples and even in the air surrounding patients in hospital with a very h ...

Recommended for you

Cooling of dialysis fluids protects against brain damage

3 hours ago

While dialysis can cause blood pressure changes that damage the brain, cooling dialysis fluids can protect against such effects. The findings come from a study appearing in an upcoming issue of the Journal of the American So ...

Two Ebola vaccines to be tested in Switzerland

3 hours ago

Clinical trials of two experimental vaccines against the deadly Ebola virus are due to begin soon in Switzerland, the country's Tropical and Public Health Institute said on Thursday.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Howard_Vickridge
not rated yet Jan 09, 2013
Brava!! Managing our gut fauna is a powerful emerging field, I reckon. I first heard of stool inoculation about 30 years ago when a colleague of my late father, a medic who suffered bad colitis, used stool from his wife to balance his colon fauna... successfully. Then, he was acting on a hunch. Wonderful to see the science evolving to make for some great therapies.